Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

Similar articles for PubMed (Select 24518087)

1.

Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer.

Ocak S, Friedman DB, Chen H, Ausborn JA, Hassanein M, Detry B, Weynand B, Aboubakar F, Pilette C, Sibille Y, Massion PP.

J Thorac Oncol. 2014 Mar;9(3):324-36. doi: 10.1097/JTO.0000000000000090.

2.

Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.

Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, Li N, Qiu B, Gao Y, Li B, Tan X, Zhou F, Wang Z, Ding D, Wang J, Sun J, Hang J, Shi S, Feng X, He F, He J.

Mol Cell Proteomics. 2012 Feb;11(2):M111.008821. doi: 10.1074/mcp.M111.008821. Epub 2011 Nov 7.

3.

Acyl-coenzyme A-binding protein regulates Beta-oxidation required for growth and survival of non-small cell lung cancer.

Harris FT, Rahman SM, Hassanein M, Qian J, Hoeksema MD, Chen H, Eisenberg R, Chaurand P, Caprioli RM, Shiota M, Massion PP.

Cancer Prev Res (Phila). 2014 Jul;7(7):748-57. doi: 10.1158/1940-6207.CAPR-14-0057. Epub 2014 May 12.

PMID:
24819876
4.

Prognostic significance of annexin II expression in non-small cell lung cancer.

Luo CH, Liu QQ, Zhang PF, Li MY, Chen ZC, Liu YF.

Clin Transl Oncol. 2013 Nov;15(11):938-46. doi: 10.1007/s12094-013-1028-y. Epub 2013 Mar 26.

PMID:
23529818
5.

Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1.

Jeong HC, Kim GI, Cho SH, Lee KH, Ko JJ, Yang JH, Chung KH.

J Proteome Res. 2011 Jan 7;10(1):269-76. doi: 10.1021/pr100714b. Epub 2010 Dec 2.

PMID:
21047053
6.

The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis.

Ren W, Mi D, Yang K, Cao N, Tian J, Li Z, Ma B.

Swiss Med Wkly. 2013 Sep 6;143:w13855. doi: 10.4414/smw.2013.13855. Review.

7.

Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry.

Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT.

Mol Cell Proteomics. 2012 Feb;11(2):M111.012112. doi: 10.1074/mcp.M111.012112. Epub 2011 Nov 17.

8.

MCPH1 Protein Expression in Normal and Neoplastic Lung Tissues.

Zhang J, Wu XB, Fan JJ, Mai L, Cai W, Li D, Yuan CF, Bu YQ, Song FZ.

Asian Pac J Cancer Prev. 2013;14(12):7295-300.

9.

A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd.

J Thorac Oncol. 2012 Dec;7(12):1755-66. doi: 10.1097/JTO.0b013e3182725fc7.

PMID:
23154546
10.

Pathobiological implications of MUC4 in non-small-cell lung cancer.

Majhi PD, Lakshmanan I, Ponnusamy MP, Jain M, Das S, Kaur S, Shimizu ST, West WW, Johansson SL, Smith LM, Yu F, Rolle CE, Sharma P, Carey GB, Batra SK, Ganti AK.

J Thorac Oncol. 2013 Apr;8(4):398-407. doi: 10.1097/JTO.0b013e3182829e06.

PMID:
23370366
11.
12.

Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients.

Song C, Gao Y, Tian Y, Han X, Chen Y, Tian DL.

Tumour Biol. 2013 Jun;34(3):1925-33. doi: 10.1007/s13277-013-0737-8. Epub 2013 Mar 20.

PMID:
23512329
13.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

PMID:
23287853
14.

CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.

Gürel D, Kargı A, Karaman I, Onen A, Unlü M.

Pathol Oncol Res. 2012 Apr;18(2):153-60. doi: 10.1007/s12253-011-9421-8. Epub 2011 Jun 18.

PMID:
21681600
15.

HSPA2 is expressed in human tumors and correlates with clinical features in non-small cell lung carcinoma patients.

Scieglinska D, Gogler-Piglowska A, Butkiewicz D, Chekan M, Malusecka E, Harasim J, Habryka A, Krawczyk Z.

Anticancer Res. 2014 Jun;34(6):2833-40.

PMID:
24922646
16.

Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer.

Lin G, Sun L, Wang R, Guo Y, Xie C.

J Thorac Oncol. 2014 Feb;9(2):170-8. doi: 10.1097/JTO.0000000000000066.

17.

Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer.

Qu Y, Yang Y, Ma D, Xiao W.

Oncol Rep. 2012 Apr;27(4):1277-83. doi: 10.3892/or.2012.1627. Epub 2012 Jan 11.

18.

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.

Han KY, Gu X, Wang HR, Liu D, Lv FZ, Li JN.

Tumour Biol. 2013 Apr;34(2):821-5. doi: 10.1007/s13277-012-0612-z. Epub 2012 Dec 11.

PMID:
23229099
19.

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.

Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.

Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.

PMID:
24710653
20.

MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.

Du L, Schageman JJ, Irnov, Girard L, Hammond SM, Minna JD, Gazdar AF, Pertsemlidis A.

J Exp Clin Cancer Res. 2010 Jun 17;29:75. doi: 10.1186/1756-9966-29-75.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk